Frequently Asked Questions About Diflucan (Fluconazole)
1.What is Diflucan (Fluconazole)?
2.How Does Diflucan Work?
3.What Conditions Does Diflucan Treat?
4.Is Diflucan Effective for Nail Fungus?
5.How is Diflucan Administered?
6.Can Diflucan Be Taken with Food?
7.How Fast Does Diflucan Work?
8.Is Diflucan Safe for Pregnant Women?
9.Are There Potential Drug Interactions with Diflucan?
10.Can Diflucan Cause Side Effects?
11.Is Diflucan Available Over-the-Counter?
12.What Should I Do If I Miss a Dose of Diflucan?
13.Can Diflucan Be Used in Children?
14.How Long Should I Take Diflucan?
15.Is Diflucan Safe for Breastfeeding Mothers?
16.Are Allergic Reactions Possible with Diflucan?
17.Can Diflucan Interfere with Birth Control?
18.Is Alcohol Consumption Safe with Diflucan?
19.How Should Diflucan Be Stored?
20.Can Diflucan Be Used for Thrush in Infants?
21.Is Diflucan Effective Against Systemic Fungal Infections?
22.Does Diflucan Impact Kidney Function?
23.What Should I Do If I Experience Severe Side Effects?
24.Can I Take Diflucan While Undergoing Chemotherapy?
25.Is Diflucan Safe for Individuals with Liver Disease?
26.Can Diflucan Cause Photosensitivity?
27.Can Diflucan Be Used Prophylactically?
28.Does Diflucan Treat Ringworm?
29.Is Diflucan Effective Against Aspergillosis?
30.Can Diflucan Be Crushed for Easier Administration?
📚 Sources Used for FAQ Content:
Information on fluconazole (the active ingredient in Diflucan) is drawn from regulatory approvals across major markets, internationally recognised treatment guidelines for fungal infections, and decades of clinical evidence including landmark trials that established fluconazole as a first-line antifungal. Diflucan was originally developed by Pfizer and remains one of the most widely prescribed antifungal medications worldwide.- U.S. FDA - Fluconazole approved 1990; original Diflucan brand by Pfizer
- European Medicines Agency (EMA) - Widely approved across EU member states
- UK MHRA, Health Canada, Australia TGA - All major Western regulators recognise fluconazole
- WHO Essential Medicines List - Includes fluconazole for systemic fungal infections and HIV-associated cryptococcal disease
- DCGI (India) - Drug Controller General of India regulation for Indian generics
- Manufacturing standards - WHO-GMP certified facilities required for all marketed fluconazole products
- IDSA Candidiasis Guidelines - Infectious Diseases Society of America clinical practice guidelines
- IDSA Cryptococcal Disease Guidelines - Management of cryptococcal infections
- WHO Treatment Recommendations - Cryptococcal meningitis treatment standards
- ESCMID guidelines - European Society of Clinical Microbiology and Infectious Diseases
- CDC fungal disease guidance - U.S. Centers for Disease Control recommendations
- ACOG vaginitis guidelines - American College of Obstetricians and Gynecologists
- Landmark fluconazole trials (1990s) - Established efficacy in candidiasis and cryptococcal disease
- NIAID-funded clinical trials - Ongoing research on antifungal pharmacology
- Cochrane systematic reviews - Multiple meta-analyses on fluconazole for vulvovaginal candidiasis, oral candidiasis, and prophylaxis
- UpToDate, DynaMed - Clinical decision support databases
- FDA FAERS and EMA EudraVigilance - Post-marketing safety surveillance
- Antifungal resistance surveillance networks - SENTRY, ARTEMIS DISK programs tracking susceptibility patterns
- LactMed lactation safety database - Pregnancy and breastfeeding safety information
FAQ Reviewed and Referenced By:
The Medication Guide content for Diflucan reflects published research and clinical guidance from internationally recognised authorities in medical mycology, infectious diseases, and antifungal pharmacotherapy. All listed authorities have substantial peer-reviewed publication records on fluconazole or fungal disease management.
University of Texas Health Science Center at San Antonio - Texas, USA
Professor of Medicine and Chief of the Division of Infectious Diseases at UT Health San Antonio. Internationally recognised mycology expert with foundational research on invasive fungal infections and antifungal therapy. Member of IDSA Practice Guideline development committees for fungal diseases.
University of Alabama at Birmingham - Alabama, USA
William E. Dismukes Professor of Medicine and Director of the UAB Mycoses Study Group. Lead author of the IDSA Clinical Practice Guideline for Management of Candidiasis. Decades of NIH-funded research on candidemia and invasive fungal infections.
University of Manchester / Global Action Fund for Fungal Infections - Manchester, UK
Professor of Infectious Diseases in Global Health at the University of Manchester and Founding Director of GAFFI (Global Action Fund for Fungal Infections). Major contributor to global mycology epidemiology and access to antifungal medications. Hundreds of peer-reviewed publications.
Wayne State University School of Medicine - Detroit, USA
Distinguished Professor of Medicine and former Dean of Wayne State University School of Medicine. Internationally recognised authority on vulvovaginal candidiasis - the most common Diflucan indication. Author of major clinical reviews and treatment guidelines on recurrent yeast infections.
University of Pittsburgh School of Medicine - Pittsburgh, USA
Professor of Medicine and Chief of Infectious Diseases at VA Pittsburgh Healthcare System. Major researcher on antifungal pharmacology, susceptibility testing, and antifungal stewardship. Active contributor to mycology guidelines and IDSA committees.
Note: this panel reflects published evidence and guidance from the listed authorities; it does not imply individual endorsement of this specific medication guide.






